Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells

被引:61
|
作者
Lin, Cheng-Wei [1 ,2 ]
Sun, Min-Siou [2 ,3 ]
Liao, Mei-Ying [2 ]
Chung, Chu-Hung [2 ]
Chi, Yi-Hsuan [2 ]
Chiou, Li-Tin [2 ]
Yu, John [2 ,4 ]
Lou, Kuo-Lung [3 ]
Wu, Han-Chung [2 ,3 ,4 ]
机构
[1] Taipei Med Univ, Sch Med, Dept Biochem, Taipei 110, Taiwan
[2] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan
[3] Natl Taiwan Univ, Coll Med, Sch Dent, Grad Inst Oral Biol, Taipei 106, Taiwan
[4] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan
关键词
GLOMERULAR EPITHELIAL-CELLS; MAJOR SIALOPROTEIN; N-WASP; TYROSINE PHOSPHORYLATION; MATRIX-METALLOPROTEINASE; ACTIN REORGANIZATION; PROSTATE-CANCER; ARP2/3; COMPLEX; STEM-CELLS; CORTACTIN;
D O I
10.1093/carcin/bgu139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic disease is the leading cause of cancer mortality. Identifying biomarkers and regulatory mechanisms is important toward developing diagnostic and therapeutic tools against metastatic cancer. In this study, we demonstrated that podocalyxin-like 1 (PODXL) is overexpressed in breast tumor cells and increased in lymph node metastatic cancer. Mechanistically, we found that the expression of PODXL was associated with cell motility and invasiveness. Suppression of PODXL in MDA-MB-231 cells reduced lamellipodia formation and focal adhesion kinase (FAK) and paxillin phosphorylation. PODXL knockdown reduced the formation of invadopodia, such as inhibiting the colocalization of F.-actin with cortactin and suppressing phosphorylation of cortactin and neural Wiskott Aldrich syndrome protein. Conversely, overexpression of PODXL in MCF7 cells induced F-actin/cortactin colocalization and enhanced invadopodia formation and activation. Invaclopoclia activity and tumor invasion in PODXL-knockdown cells are similar to that in cortactin-knockdown cells. We further found that the DTHL motif in PODXL is crucial for regulating cortactin phosphorylation and Rac1/Cdc42 activation. Inhibition of Rac1/Cdc42 impeded PODXL-mediated cortactin activation and FAK and paxillin phosphorylation. Moreover, inhibition of PODXL in MDA-MB-231 cells significantly suppressed tumor colonization in the lungs and distant metastases, similar to those in cortactin-knockdown cells. These findings show that overexpression of PODXL enhanced invadopodia formation and tumor metastasis by inducing Rac1/Cdc42/cortactin signaling network.
引用
收藏
页码:2425 / 2435
页数:11
相关论文
共 35 条
  • [31] Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells
    Aksamitiene, Edita
    Achanta, Sirisha
    Kolch, Walter
    Kholodenko, Boris N.
    Hoek, Jan B.
    Kiyatkin, Anatoly
    CELLULAR SIGNALLING, 2011, 23 (11) : 1794 - 1805
  • [32] ROS-generating oxidase NOX1 promotes the self-renewal activity of CD133+thyroid cancer cells through activation of the Akt signaling
    Wang, Cong
    Wang, Zhenglin
    Liu, Wei
    Ai, Zhilong
    CANCER LETTERS, 2019, 447 : 154 - 163
  • [33] RETRACTED: Vascular Endothelial Growth Factor Receptor-1 Activation Promotes Migration and Invasion of Breast Cancer Cells through Epithelial-Mesenchymal Transition (Retracted Article)
    Ning, Qian
    Liu, Caigang
    Hou, Lei
    Meng, Min
    Zhang, Xiaojin
    Luo, Minna
    Shao, Shan
    Zuo, Xiaoxiao
    Zhao, Xinhan
    PLOS ONE, 2013, 8 (06):
  • [34] Lysophosphatidic Acid Induces MDA-MB-231 Breast Cancer Cells Migration through Activation of PI3K/PAK1/ERK Signaling
    Du, Jun
    Sun, Chongqi
    Hu, Zhenzhen
    Yang, Yu
    Zhu, Yichao
    Zheng, Datong
    Gu, Luo
    Lu, Xiang
    PLOS ONE, 2010, 5 (12):
  • [35] TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis
    Pang, M-F
    Georgoudaki, A-M
    Lambut, L.
    Johansson, J.
    Tabor, V.
    Hagikura, K.
    Jin, Y.
    Jansson, M.
    Alexander, J. S.
    Nelson, C. M.
    Jakobsson, L.
    Betsholtz, C.
    Sunds, M.
    Karlsson, M. C. I.
    Fuxe, J.
    ONCOGENE, 2016, 35 (06) : 748 - 760